Company: PCRX
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001104659-25-041219
Chunk: 57

Company: Pacira BioSciences, Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 57
---
 ​ | ​ | ​ | ​ | 217,523 | ​              | ​ |
| Jonathan Slonin             | ​ | ​ | ​ | ​ | 227,295 | ​              | ​ |

(1) Messrs. Stack and Reinhart did not participate due to their departures, and Mr. Cross did not participate as he began employment with the Company on October 21, 2024.

Pacira BioSciences, Inc. 2025 Proxy Statement | 69

TABLE OF CONTENTS Executive Compensation

| ​ | ​ | Any payout amounts earned during a cash LTIP performance period are based on a percentage of each participants base salary at the time the cash LTIP was approved by the People & Compensation Committee. These earned payouts will then vest in full only after a three-year vesting period, subject to the participant’s continued employment (except in the case of death or disability during the vesting period). | ​ | ​ |

Equity Incentive Awards We believe that our long-term performance is enhanced through equity awards to our named executive officers. Equity awards motivate and incentivize our named executive officers: 1. reward our named executive officers for maximizing stockholder value over time and provide our named executive officers with a strong link to our long-term performance by enhancing their accountability for long-term decision making; 2. ensure focus on long-term value creation and our strategic objectives, and creates an ownership culture by aligning the interests of our named executive officers with the creation of long-term value for our stockholders; 3. align the long-term interests of our named executive officers with those of our stockholders; and 4. further our goal of executive retention. All equity incentive awards granted to our named executive officers are approved by our People & Compensation Committee. Equity incentive awards to our named executive officers are made in the form of stock options with exercise prices equal to the closing market price of our common stock on the date of grant and time-vesting RSUs. The People & Compensation Committee designed the long-term incentive opportunity to motivate and reward our executive officers to achieve multi-year strategic goals and to deliver sustained long-term value to stockholders. For 2024, the People & Compensation Committee determined that 100% RSUs were the best vehicle to use for grants to our existing named executive officers, as they motivate and incentivize our named executive officers because they have upside potential but also provide a retentive benefit and encourage our executives to focus on the long-term success of the Company because they